A critical goal for the Phase 3 clinical trial is also to ensure that the pool of the vaccine test subjects reflects the nation’s diversity, including minorities, older Americans and people with preexisting health conditions. It’s all the more important given the disparate impact the pandemic has had on people who are Black or Latino, as well as other racial minorities.
GWU’s covid-19 clinical trial has met one early goal — getting Black and Latino people to join
Latest News
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV